Dr Debashis Sarker Academics Senior Lecturer and Consultant in Medical Oncology Contact details debashis.sarker@kcl.ac.uk
Serum Immunoglobulin G Is Associated With Decreased Risk of Pancreatic Cancer in the Swedish AMORIS Study Sollie, S., Santaolalla, A., Michaud, D. S., Sarker, D., Karagiannis, S. N., Josephs, D. H., Hammar, N., Walldius, G., Garmo, H., Holmberg, L., Jungner, I. & Van Hemelrijck, M., 28 Feb 2020, In : Frontiers in oncology. 10, 263. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.3389/fonc.2020.00263 Serum immunoglobulin G is associated with decreased risk of pancreatic cancer in the Swedish AMORIS study Sollie, S., Santaolalla, A., Michaud, D. S., Sarker, D., Karagiannis, S. N., Josephs, D. H., Hammar, N., Walldius, G., Garmo, H., Holmberg, L., Jungner, I. & Van Hemelrijck, M., 14 Feb 2020, (Accepted/In press) In : Frontiers in oncology. Research output: Contribution to journal - Article Serum Immunoglobulin G Is Associated With Decreased Risk of Pancreatic Cancer in the Swedish AMORIS Study Sollie, S., Santaolalla, A., Michaud, D. S., Sarker, D., Karagiannis, S. N., Josephs, D. H., Hammar, N., Walldius, G., Garmo, H., Holmberg, L., Jungner, I. & Van Hemelrijck, M., 2020, In : Frontiers in oncology. 10, p. 263 Research output: Contribution to journal - Article. DOIs: https://doi.org/10.3389/fonc.2020.00263 First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma Kim, R. D., Sarker, D., Meyer, T., Yau, T., Macarulla, T., Park, J. W., Choo, S. P., Hollebecque, A., Sung, M. W., Lim, H. Y., Mazzaferro, V., Trojan, J., Zhu, A. X., Yoon, J. H., Sharma, S., Lin, Z. Z., Chan, S. L., Faivre, S., Feun, L. G., Yen, C. J. & 15 others, Dufour, J. F., Palmer, D. H., Llovet, J. M., Manoogian, M., Tugnait, M., Stransky, N., Hagel, M., Kohl, N. E., Lengauer, C., Sherwin, C. A., Schmidt-Kittler, O., Hoeflich, K. P., Shi, H., Wolf, B. B. & Kang, Y. K., 1 Dec 2019, In : Cancer discovery. 9, 12, p. 1696-1707 12 p. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.1158/2159-8290.CD-19-0555 Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort study Sollie, S., Michaud, D. S., Sarker, D., Karagiannis, S. N., Josephs, D. H., Hammar, N., Santaolalla, A., Walldius, G., Garmo, H., Holmberg, L., Jungner, I. & Van Hemelrijck, M., 29 Aug 2019, In : BMC Cancer. 19, 1, 858. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.1186/s12885-019-6082-6 Hepatocellular Carcinoma as a Complication of Vascular Disease of the Liver After Fontan Procedure Mazzarelli, C., Cannon, M. D., Hudson, M., Heaton, N., Sarker, D., Kane, P., Quaglia, A. & Suddle, A., 1 Feb 2019, In : Hepatology. 69, 2, p. 911-913 3 p. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.1002/hep.30194 Delayed adverse events in phase I trials of molecularly targeted and cytotoxic agents Jordan, E. J., Spicer, J. & Sarker, D., 21 Sep 2018, In : Oncotarget. 9, 74, p. 33961-33971 11 p. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.18632%2Foncotarget.26104 First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer Massard, C., Azaro, A., Soria, J. C., Lassen, U., Le Tourneau, C., Sarker, D., Smith, C., Ohnmacht, U., Oakley, G., Patel, B. K. R., Yuen, E. S. M., Benhadji, K. A. & Rodon, J., 1 Sep 2018, In : Annals of Oncology. 29, 9, p. 1911-1917 7 p. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.1093/annonc/mdy244 A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors O'Brien, M. E. R., Sarker, D., Bhosle, J., Thillai, K., Yap, T. A., Uttenreuther-Fischer, M., Pemberton, K., Jin, X., Wiebe, S., De Bono, J. & Spicer, J., 7 Aug 2018, In : Cancer Chemotherapy and Pharmacology. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.1007/s00280-018-3661-1 Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., Sarker, D., Verset, G., Chan, S. L., Knox, J., Daniele, B., Webber, A. L., Ebbinghaus, S. W., Ma, J., Siegel, A. B., KEYNOTE-224 investigators & 31 others, Cheng, A., Kudo, M., Alistar, A., Asselah, J., Blanc, J., Borbath, I., Cannon, T., Chung, K., Cohn, A., Cosgrove, D. P., Damjanov, N., Gupta, M., Karino, Y., Karwal, M., Kaubisch, A., Kelley, R., Van Laethem, J., Larson, T., Lee, J., Li, D., Manhas, A., Manji, G. A., Numata, K., Parsons, B., Paulson, A. S., Pinto, C., Ramirez, R., Ratnam, S., Rizell, M., Rosmorduc, O. & Sada, Y., Jun 2018, In : The Lancet Oncology. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.1016/S1470-2045(18)30351-6 View all publications